StockData
PTC Therapeutics, Inc. logo

PTC Therapeutics, Inc. (PTCT) stock

PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3028% above fair value
$60.23−0.13 (-0.22%)

Close on Nov 18, 2026Market cap $5.03BP/E –Yield –

PTC Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

PTC Therapeutics's revenue for the twelve months ending Sep 30, 2026 was $1.16B, down 35.1% year over year. For fiscal 2025 it was $1.73B, up 114.5% from the year before. Over ten years it grew 47.0% a year on average. The highest annual figure on record is $1.73B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.73B+114.5%
FY2024Dec 31, 2024$806.78M-14.0%
FY2023Dec 31, 2023$937.82M+34.2%
FY2022Dec 31, 2022$698.80M+29.7%
FY2021Dec 31, 2021$538.59M+41.4%
FY2020Dec 31, 2020$380.77M+24.0%
FY2019Dec 31, 2019$306.98M+16.0%
FY2018Dec 31, 2018$264.73M+36.2%
FY2017Dec 31, 2017$194.39M+135.0%
FY2016Dec 31, 2016$82.71M+124.9%
FY2015Dec 31, 2015$36.77M+45.6%
FY2014Dec 31, 2014$25.25M-27.2%
FY2013Dec 31, 2013$34.70M+2.2%
FY2012Dec 31, 2012$33.95M-67.8%
FY2011Dec 31, 2011$105.41M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$357.81M+69.6%
Q2 FY2026Jun 30, 2026$360.52M+101.5%
Q1 FY2026Mar 31, 2026$272.55M-76.8%
Q4 FY2025Dec 31, 2025$164.68M-22.7%
Q3 FY2025Sep 30, 2025$211.01M+7.2%
Q2 FY2025Jun 30, 2025$178.88M-4.2%
Q1 FY2025Mar 31, 2025$1.18B+459.7%
Q4 FY2024Dec 31, 2024$213.17M-30.6%
Q3 FY2024Sep 30, 2024$196.79M+0.1%
Q2 FY2024Jun 30, 2024$186.70M-12.7%
Q1 FY2024Mar 31, 2024$210.12M-4.7%
Q4 FY2023Dec 31, 2023$307.06M+83.4%
Q3 FY2023Sep 30, 2023$196.58M-9.5%
Q2 FY2023Jun 30, 2023$213.81M+29.2%
Q1 FY2023Mar 31, 2023$220.38M+48.2%
Q4 FY2022Dec 31, 2022$167.41M+1.3%
Q3 FY2022Sep 30, 2022$217.13M+56.5%
Q2 FY2022Jun 30, 2022$165.53M+41.9%
Q1 FY2022Mar 31, 2022$148.74M+26.1%
Q4 FY2021Dec 31, 2021$165.23M+39.0%
Q3 FY2021Sep 30, 2021$138.74M+17.2%
Q2 FY2021Jun 30, 2021$116.68M+55.1%
Q1 FY2021Mar 31, 2021$117.94M+72.8%
Q4 FY2020Dec 31, 2020$118.86M+23.2%
Q3 FY2020Sep 30, 2020$118.40M+65.8%
Q2 FY2020Jun 30, 2020$75.24M-12.0%
Q1 FY2020Mar 31, 2020$68.26M+27.4%
Q4 FY2019Dec 31, 2019$96.46M+12.4%
Q3 FY2019Sep 30, 2019$71.42M+33.3%
Q2 FY2019Jun 30, 2019$85.52M+24.4%
Q1 FY2019Mar 31, 2019$53.58M-4.4%
Q4 FY2018Dec 31, 2018$85.83M+48.1%
Q3 FY2018Sep 30, 2018$53.59M+28.3%
Q2 FY2018Jun 30, 2018$68.74M+43.5%
Q1 FY2018Mar 31, 2018$56.06M+112.0%
Q4 FY2017Dec 31, 2017$57.95M+130.7%
Q3 FY2017Sep 30, 2017$41.78M–
Q2 FY2017Jun 30, 2017$47.89M–
Q1 FY2017Mar 31, 2017$26.44M–
Q4 FY2016Dec 31, 2016$25.12M–

More PTC Therapeutics figures

See a number that looks wrong?